Eli Lilly shares are trading higher in sympathy with Novo Nordisk, which halted its semaglutide FLOW kidney trial on early signs of efficiency. Eli Lilly makes a similar GLP-1 drug to Novo's Ozempic called Mounjaro.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's shares are trading higher due to positive developments in Novo Nordisk's semaglutide FLOW kidney trial. Eli Lilly produces a similar GLP-1 drug to Novo's Ozempic, known as Mounjaro.
October 11, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's stock is trading higher due to positive developments in a similar drug trial by Novo Nordisk.
Eli Lilly's stock is trading higher due to positive developments in Novo Nordisk's semaglutide FLOW kidney trial. Since Eli Lilly produces a similar GLP-1 drug, this positive news for Novo Nordisk is also seen as a positive indicator for Eli Lilly, leading to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100